Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 16, 2026
RE/MAX Holdings (RMAX) Eyes the $15 Level: +19.5% Upside Potential from Recent Close

RE/MAX Holdings (RMAX) Eyes the $15 Level: +19.5% Upside Potential from Recent Close

Key Takeaways

  • Selected price target: $15 per share, roughly 19.5% above RMAX’s latest close of $12.55.
  • Strongest bullish factor: The pending acquisition by The Real Brokerage values RMAX at $13.80 per share in cash or stock, creating a transaction-driven anchor of interest.
  • Biggest obstacle: That same $13.80 merger consideration may act as a near-term ceiling; reaching $15 likely requires improved terms, a higher stock-component value, or a standalone re-rating.
  • Key levels: Support appears in the $12.10–$12.30 area; resistance sits at the 52-week high of $13.35, followed by $13.80 and then $15.
  • Key takeaway: $15 is not the base-case expectation under current deal terms, but it is a realistic stretch scenario if transaction dynamics or operating momentum improve.

Why the $15 Level Stands Out

RMAX has already recovered sharply from its 52-week low of $5.46 set in April 2026 to a 52-week high of $13.35 in mid-August. With the stock consolidating just below that high, $15 stands out as the next major psychological threshold. The level has also appeared in public market commentary as a potential recovery objective, even though current published analyst targets generally sit lower.

Because $15 sits above both the 52-week high and the $13.80 per-share merger value, clearing that area would signal that the market sees value beyond the announced transaction—an important distinction for a stock trading with merger-driven dynamics.

Company Overview and Market Position

RE/MAX Holdings is a franchisor rather than a traditional brokerage owner. It generates revenue through real estate franchise fees and royalties under the RE/MAX brand, mortgage brokerage franchising through Motto Mortgage, loan-processing technology through wemlo, and marketing-fund programs. The company has a global footprint, with roughly 149,000 agents reported in early 2026.

Fundamentals remain mixed. Second-quarter 2026 revenue came in at $68.5 million, below consensus estimates of about $73.5 million, while adjusted earnings per share (EPS) of $0.32 also missed the roughly $0.39 consensus. Adjusted EBITDA of $22.9 million shows the franchise model still generates cash flow, but declining revenue and softer agent counts in the U.S. and Canada illustrate why a larger technology-enabled partner may be needed. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The $13.80 Merger Anchor

In late April 2026, The Real Brokerage Inc. (NASDAQ: REAX) agreed to acquire RE/MAX Holdings in a cash-and-stock transaction. Each RMAX shareholder may elect to receive $13.80 in cash or 5.152 shares of the combined company, Real REMAX Group, subject to proration that caps total cash consideration between $60 million and $80 million. The deal is expected to close in the second half of 2026, subject to shareholder, regulatory, and court approvals.

The combined entity would have generated about $2.3 billion in pro forma 2025 revenue and about $157 million in adjusted EBITDA, with management targeting around $30 million in annual cost synergies by 2027. Those economics explain why RMAX has traded toward the $13.80 level—but they also explain why standalone upside above $13.80 is not currently the base case.

What Could Drive RMAX Toward $15

  • Stock-component appreciation: Because shareholders can elect 5.152 shares of Real REMAX Group, the value of that consideration can rise above $13.80 if the combined company’s shares outperform.
  • A superior proposal: A higher bid or revised terms could force the market to reprice RMAX beyond the current deal anchor.
  • Operating improvement: Better agent retention, stabilizing U.S. and Canadian fee revenue, or a broader housing recovery could support a higher standalone valuation.
  • Technical breakout: A decisive move through $13.35 and $13.80 would remove two visible resistance levels and could bring the psychological $15 area into focus.

What Could Prevent the Move

  • Deal ceiling: As long as the $13.80 consideration defines value, risk arbitrage may keep RMAX capped just below that level, adjusted for closing risk.
  • Fundamental softness: Revenue has been declining, and second-quarter results missed expectations, limiting the case for a standalone premium.
  • Industry headwinds: Commission-structure changes following the National Association of Realtors settlement, affordability pressures, and elevated mortgage rates continue to weigh on traditional real estate franchisors.
  • Analyst targets: Published 12-month price targets generally range from about $9 to $14.49, with consensus estimates below the $15 threshold.

Technical Levels That Matter

RMAX’s most important support zone sits near $12.10–$12.30, an area where the stock consolidated before its most recent push higher. Below that, the $11.30–$11.40 zone represents the early-August breakout area and a more significant demand zone. On the upside, $13.35 is the immediate 52-week high and the clearest near-term resistance. Above that, $13.80 is the merger-implied value, and $15 is the next major psychological target.

A sustained hold above $12.30 would keep the recent uptrend intact, while a decisive break below $11.30 would suggest the merger-related optimism is fading and put the focus back on the lower end of the range. From what I see, monitoring these levels closely helps frame the risk-reward around the $15 scenario.

Final Assessment

Can RE/MAX Holdings reach $15? The path exists, but it is more demanding than reaching the $13.80 transaction value. The strongest support comes from the merger, the company’s global franchise network, and the combined entity’s synergy potential. The largest obstacles are the deal-level anchor, softer revenue and earnings momentum, and a real estate industry still adjusting to commission and affordability pressures. Investors should monitor merger closing progress, the implied value of the stock consideration, quarterly agent-count and revenue trends, and whether RMAX can clear $13.35 on a closing basis. Until then, $15 remains a credible stretch scenario rather than the central expectation.

Tickeron AI Daily Buy/Sell Signals in My Research Process

I regularly turn to Tickeron’s AI Daily Buy/Sell Signals to stay on top of stocks like RMAX. The tool uses artificial intelligence to monitor thousands of securities and generate Buy, Sell, or Hold signals based on technical behavior and market conditions. It helps me place short-term price action around the $13.35 and $13.80 resistance levels in a broader, data-driven context without replacing my own analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RMAX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for RMAX turns positive, indicating new upward trend

RMAX saw its Momentum Indicator move above the 0 level on August 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for RMAX just turned positive on August 07, 2026. Looking at past instances where RMAX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

RMAX moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RMAX crossed bullishly above the 50-day moving average on August 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RMAX advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RMAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RMAX broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RMAX entered a downward trend on August 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RMAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.603) is normal, around the industry mean (3.871). RMAX has a moderately high P/E Ratio (538.500) as compared to the industry average of (119.785). RMAX's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (0.712). Dividend Yield (0.019) settles around the average of (0.043) among similar stocks. P/S Ratio (0.923) is also within normal values, averaging (5.524).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RMAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Industry description

Activities range from the renovation and re-lease of existing buildings to the purchase of raw land and the sale of developed land or parcels to others. Demand for land development business is driven by GDP growth, employment rates, interest rates, and access to/cost of capital. For individual companies in this industry, proper cost estimation and successful bidding play critical roles in their profitability. Large companies could potentially have greater access to capital, while smaller companies can specialize in a specific geographic area or market niche. CBRE Group, VICI Properties Inc and Brookfield Property Partners L.P. are some of the large companies in this industry.

Market Cap

The average market capitalization across the Real Estate Development Industry is 2.95B. The market cap for tickers in the group ranges from 487 to 165.37B. TMHTY holds the highest valuation in this group at 165.37B. The lowest valued company is SHIOF at 487.

High and low price notable news

The average weekly price growth across all stocks in the Real Estate Development Industry was 0%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -9%. DOUG experienced the highest price growth at 14%, while LRHC experienced the biggest fall at -29%.

Volume

The average weekly volume growth across all stocks in the Real Estate Development Industry was 5%. For the same stocks of the Industry, the average monthly volume growth was -64% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 71
Price Growth Rating: 59
SMR Rating: 85
Profit Risk Rating: 92
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
RMAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of real estate brokerage services

Industry RealEstateDevelopment

Profile
Details
Industry
Real Estate Development
Address
5075 South Syracuse Street
Phone
+1 303 770-5531
Employees
544
Web
https://www.remax.com
Interact to see
Advertisement
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Cincinnati Financial (CINF) reports Q4 2025 earnings on February 9, 2026, after market close, with consensus EPS of $2.86–$2.89 and revenue around $2.91 billion. Allstate (ALL) recently reported Q4 2025 EPS of $14.31, well above the $8.72 estimate, with revenue of $17.3 billion on February 4, 2026.
(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside. Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
CME Group delivered record 2025 revenue of $6.52 billion, up 6% year-over-year. Q4 adjusted EPS of $2.77 exceeded expectations.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.